Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL"

By Insights from 2023 ASH Annual Meeting FEATURING Kerry Rogers
By Insights from 2023 ASH Annual Meeting FEATURING Kerry Rogers
61 views
December 17, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Leukemia
05:08
Insights from 2023 ASH Annual Meeting

Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOI…

Feat. P. Ghia
06:13
Insights from 2023 ASH Annual Meeting

QuANTUM-First Trial - PROs in FLT3-ITD Mutated AML Receiving Quizart…

Feat. E. Oliva
20:28
Insights from 2023 ASH Annual Meeting

Clinically-Relevant Updates in ALL in Adults From ASH 2023

Feat. R. Cassaday
08:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of CLL - Highlights & Key Takea…

Feat. V. Yazbeck
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:20
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Future Paradigm of HMA + Ven or Targete…

Feat. J. Watts
06:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "NPM1-Mutated Myeloid Neoplasms - Outcomes W…

Feat. G. Montalban Bravo
09:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatin…

Feat. J. Cortés
11:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Maintenance Rux Is Associated With Low Rate…

Feat. Z. DeFilipp
09:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax + Pegcrisantaspase in R/R AML - …

Feat. Y. Liu
13:15
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Bezuclastinib (CGT9486), a Novel KIT D816V …

Feat. P. Vachhani
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
06:49
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Ad…

Feat. M. Luskin
07:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R…

Feat. M. Luskin
04:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatme…

Feat. I. Aldoss
05:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2A…

Feat. I. Aldoss
09:19
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Ob…

Feat. M. Fürstenau
13:31
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "COVALENT-101 Study - Covalent Menin Inhibit…

Feat. J. Lancet
01:44
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Optimizing Outcomes With Myeloablative Cond…

Feat. C. Oliai
07:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …

Feat. E. Atallah
10:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Comparison of Venetoclax Based Treatments f…

Feat. B. Heyman
18:27
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "QuANTUM-First - Safety by Treatment Phase a…

Feat. H. Erba
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
04:21
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Improving Long-Term Outcomes With Intensive…

Feat. C. Röllig
03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
11:00
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) &…

Feat. H. Atluri
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
08:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Tre…

Feat. D. Yeung
14:40
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and On…

Feat. E. Curran
14:10
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Relapse Incidence Post Unrelated alloSCT Wi…

Feat. A. Nagler
06:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…

Feat. M. Shadman
07:04
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Impact of Ibrutinib Dose Reduction on Durat…

Feat. M. Shadman
08:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosiden…

Feat. A. Ambinder
08:26
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Pirtobrutinib in Post-cBTKi CLL/SLL - 30 Mo…

Feat. J. Woyach
06:17
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Maintenance Therapy Following Rev…

Feat. A. Zucenka
05:12
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With …

Feat. N. Shah
07:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy A…

Feat. N. Ghosh
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effect of Ibrutinib Flexible Dosing Strateg…

Feat. N. Ghosh
07:22
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Hypertension in Pts With CLL and Other Heme…

Feat. A. Ferrajoli
09:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & …

Feat. C. Chen
07:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to…

Feat. K. Rogers
07:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Understanding Differential Technologies for…

Feat. J. Cloos
10:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Quizartinib, Venetoclax, & Decitabine T…

Feat. M. Yilmaz
07:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Re…

Feat. M. Amaya
06:57
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Combination Treatment With Sonrotoclax (BGB…

Feat. M. Ann Anderson
05:28
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Performance of the Molecular International …

Feat. K. Chien
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay